<p>Psoriasis is a chronic, immune-mediated inflammatory skin disorder characterized by erythematous plaques and hyperproliferation of keratinocytes. Despite advancements in topical, systemic, and biologic therapies, current treatments are often limited by adverse effects, poor skin penetration, and inadequate targeting. Polymeric nanocarriers have emerged as a promising solution to overcome these limitations by enabling controlled, site-specific, and sustained delivery of anti-psoriatic agents. This review explores the evolving role of polymeric nanocarriers such as nanoparticles, micelles, nanogels, and hybrid systems in enhancing drug solubility, skin permeability, and therapeutic efficacy. The mechanisms of action, types of polymers used (natural and synthetic), formulation strategies, and advantages over conventional therapies are comprehensively discussed. In-depth analysis of preclinical and experimental studies highlights the improved safety profiles, enhanced drug retention, and reduced systemic toxicity of polymeric nanocarriers. Additionally, we examine the challenges related to biosafety, drug loading, regulatory hurdles, and clinical translation. The review concludes with future perspectives that emphasize the need for advanced clinical trials and interdisciplinary collaboration to facilitate the successful integration of polymeric nanocarriers into mainstream psoriasis management. </p>